Resmed CFO Brett Sandercock to Retire on May 4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy RMD?
Resmed announced that Brett Sandercock, CFO, plans to retire effective May 4. After conducting a search, Aaron Bloomer has been appointed as his successor. Bloomer joinsResmedfrom Exact Sciences, where he served as CFO.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMD
Wall Street analysts forecast RMD stock price to rise
11 Analyst Rating
6 Buy
5 Hold
0 Sell
Moderate Buy
Current: 206.890
Low
260.00
Averages
294.00
High
345.00
Current: 206.890
Low
260.00
Averages
294.00
High
345.00
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RESMED INC. ANNOUNCES NEW OFFICER APPOINTMENT
- New Officer Appointment: A new officer has been appointed to a significant position within the organization.
- Responsibilities and Goals: The new officer is expected to bring fresh perspectives and drive initiatives aligned with the organization's objectives.
- Impact on the Team: This appointment is anticipated to enhance team dynamics and improve overall performance.
- Future Developments: The organization looks forward to the contributions of the new officer in upcoming projects and strategies.
See More
Analysis of Companies with Strong Cash Flow
- Hudson Technologies Decline: Hudson Technologies has a net cash position of $34.17 million, representing 12.9% of its market cap, yet its sales have declined by an average of 7.6% annually over the past two years, indicating adverse market trends, while its earnings per share have fallen by 39.1% annually, suggesting deteriorating profitability.
- ResMed's Sustained Growth: ResMed boasts a net cash position of $817.3 million, or 2.6% of its market cap, with constant currency growth averaging 9.1% over the past two years, demonstrating its ability to expand globally, and its earnings per share have increased by 15.2% annually, indicating strong profitability.
- Texas Pacific Land's Asset Strength: Texas Pacific Land holds a net cash position of $127 million, accounting for 0.4% of its market cap, with annual revenue growth of 26.2% over the last decade, reflecting increased market share, and a gross margin of 95% highlights its superior unit economics.
- Investment Flexibility: All three companies possess strong cash flows, with Hudson Technologies facing challenges, while ResMed and Texas Pacific Land show promising growth potential, allowing them to leverage their cash flows for investments or share buybacks.
See More
U.S. Stocks Close: S&P 500 Hits All-Time High
- S&P 500 Strong Performance: The S&P 500 index rose by 0.29%, reaching an all-time high, driven by Apple's forecast of stronger-than-expected Q2 revenue, which boosted market sentiment and indicated increased investor confidence in tech stocks.
- Atlassian Stock Surge: Atlassian's stock soared over 29% after reporting Q3 revenue of $1.79 billion, exceeding the market expectation of $1.69 billion, highlighting a robust recovery in the software sector that may attract more investor interest.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell more than 3%, easing inflation concerns, although trade tensions resurfaced with President Trump's threat to raise tariffs on EU auto imports, potentially negatively affecting market sentiment.
- Economic Data Influencing Stocks: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, indicating signs of economic slowdown, despite the majority of companies reporting Q1 earnings that exceeded expectations, leaving the overall market facing uncertainty.
See More
Mixed Performance in US Indices as Apple’s Strong Earnings Boost Market
- Apple's Strong Earnings: Apple Inc. (AAPL) reported Q2 revenue of $111.18 billion, exceeding the consensus of $109.66 billion, and forecasted Q3 revenue growth of 14% to 17%, significantly above the expected 9.1%, which propelled the Dow Jones Industrial Average up over 4%.
- Software Stocks Surge: Atlassian (TEAM) posted Q3 revenue of $1.79 billion, surpassing the consensus of $1.69 billion, leading to a stock price increase of over 20%, which not only boosted the software sector but also enhanced investor confidence in tech stocks.
- Oil Price Volatility: WTI crude oil prices fell more than 3% due to developments in the US-Iran agreement, temporarily easing inflation concerns and contributing to stock market gains, highlighting the energy market's influence on the overall economy.
- Weak Manufacturing Data: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, while the prices paid sub-index rose to a four-year high of 84.6, indicating increasing price pressures that could impact Federal Reserve policy decisions.
See More
RESMED INC: JEFFERIES LOWERS TARGET PRICE FROM $290 TO $240
- Price Adjustment: Jeffries has reduced the target price for a specific stock from $290 to $240.
- Market Impact: This adjustment may influence investor sentiment and trading strategies related to the stock in question.
See More
ResMed Reports Strong Q3 2026 Earnings with Strategic Acquisition
- Strong Financial Performance: ResMed reported $1.43 billion in revenue for Q3 FY 2026, reflecting an 11% year-over-year growth and a 21% increase in non-GAAP earnings per share, indicating robust market performance and enhanced profitability.
- Gross Margin Expansion: The gross margin improved by 290 basis points year-over-year and 50 basis points sequentially to 62.8%, which not only demonstrates effective cost control but also lays a solid foundation for future profit growth.
- Strategic Acquisition Plan: The company announced a $340 million acquisition of Noctrix, expected to close around June 1, 2026, which will enhance ResMed's competitive position in the market and drive long-term growth.
- Future Outlook: Despite pressures from rising component costs, management still anticipates gross margins to remain between 62% and 63% for FY 2026, reflecting confidence in profitability, while planning to repurchase at least $175 million in shares during Q4.
See More
RESMED INC. ANNOUNCES NEW OFFICER APPOINTMENT
- New Officer Appointment: A new officer has been appointed to a significant position within the organization.
- Responsibilities and Goals: The new officer is expected to bring fresh perspectives and drive initiatives aligned with the organization's objectives.
- Impact on the Team: This appointment is anticipated to enhance team dynamics and improve overall performance.
- Future Developments: The organization looks forward to the contributions of the new officer in upcoming projects and strategies.
See More
Analysis of Companies with Strong Cash Flow
- Hudson Technologies Decline: Hudson Technologies has a net cash position of $34.17 million, representing 12.9% of its market cap, yet its sales have declined by an average of 7.6% annually over the past two years, indicating adverse market trends, while its earnings per share have fallen by 39.1% annually, suggesting deteriorating profitability.
- ResMed's Sustained Growth: ResMed boasts a net cash position of $817.3 million, or 2.6% of its market cap, with constant currency growth averaging 9.1% over the past two years, demonstrating its ability to expand globally, and its earnings per share have increased by 15.2% annually, indicating strong profitability.
- Texas Pacific Land's Asset Strength: Texas Pacific Land holds a net cash position of $127 million, accounting for 0.4% of its market cap, with annual revenue growth of 26.2% over the last decade, reflecting increased market share, and a gross margin of 95% highlights its superior unit economics.
- Investment Flexibility: All three companies possess strong cash flows, with Hudson Technologies facing challenges, while ResMed and Texas Pacific Land show promising growth potential, allowing them to leverage their cash flows for investments or share buybacks.
See More
U.S. Stocks Close: S&P 500 Hits All-Time High
- S&P 500 Strong Performance: The S&P 500 index rose by 0.29%, reaching an all-time high, driven by Apple's forecast of stronger-than-expected Q2 revenue, which boosted market sentiment and indicated increased investor confidence in tech stocks.
- Atlassian Stock Surge: Atlassian's stock soared over 29% after reporting Q3 revenue of $1.79 billion, exceeding the market expectation of $1.69 billion, highlighting a robust recovery in the software sector that may attract more investor interest.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell more than 3%, easing inflation concerns, although trade tensions resurfaced with President Trump's threat to raise tariffs on EU auto imports, potentially negatively affecting market sentiment.
- Economic Data Influencing Stocks: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, indicating signs of economic slowdown, despite the majority of companies reporting Q1 earnings that exceeded expectations, leaving the overall market facing uncertainty.
See More
Mixed Performance in US Indices as Apple’s Strong Earnings Boost Market
- Apple's Strong Earnings: Apple Inc. (AAPL) reported Q2 revenue of $111.18 billion, exceeding the consensus of $109.66 billion, and forecasted Q3 revenue growth of 14% to 17%, significantly above the expected 9.1%, which propelled the Dow Jones Industrial Average up over 4%.
- Software Stocks Surge: Atlassian (TEAM) posted Q3 revenue of $1.79 billion, surpassing the consensus of $1.69 billion, leading to a stock price increase of over 20%, which not only boosted the software sector but also enhanced investor confidence in tech stocks.
- Oil Price Volatility: WTI crude oil prices fell more than 3% due to developments in the US-Iran agreement, temporarily easing inflation concerns and contributing to stock market gains, highlighting the energy market's influence on the overall economy.
- Weak Manufacturing Data: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, while the prices paid sub-index rose to a four-year high of 84.6, indicating increasing price pressures that could impact Federal Reserve policy decisions.
See More
RESMED INC: JEFFERIES LOWERS TARGET PRICE FROM $290 TO $240
- Price Adjustment: Jeffries has reduced the target price for a specific stock from $290 to $240.
- Market Impact: This adjustment may influence investor sentiment and trading strategies related to the stock in question.
See More
ResMed Reports Strong Q3 2026 Earnings with Strategic Acquisition
- Strong Financial Performance: ResMed reported $1.43 billion in revenue for Q3 FY 2026, reflecting an 11% year-over-year growth and a 21% increase in non-GAAP earnings per share, indicating robust market performance and enhanced profitability.
- Gross Margin Expansion: The gross margin improved by 290 basis points year-over-year and 50 basis points sequentially to 62.8%, which not only demonstrates effective cost control but also lays a solid foundation for future profit growth.
- Strategic Acquisition Plan: The company announced a $340 million acquisition of Noctrix, expected to close around June 1, 2026, which will enhance ResMed's competitive position in the market and drive long-term growth.
- Future Outlook: Despite pressures from rising component costs, management still anticipates gross margins to remain between 62% and 63% for FY 2026, reflecting confidence in profitability, while planning to repurchase at least $175 million in shares during Q4.
See More
